Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (https://castletestinfo.com).
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions on the risk of sentinel lymph node positivity and the intensity of follow-up, surveillance imaging, referral and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and sentinel lymph node status and is supported by consistent evidence in over 25 publications including two meta-analyses showing Level 1A evidence classification.
DecisionDx® DiffDx-Melanoma is a new gene expression profile test designed to reduce diagnostic uncertainty by providing a highly accurate and objective evaluation. DiffDx-Melanoma adds diagnostic clarity leading to a more confident diagnosis and a clearer treatment path for patients.
DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona (www.CastleBiosciences.com).
Featured Content
